Capstone Investment Advisors
LXRX icon

Capstone Investment Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Capstone Investment Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,400
Closed -$163K – 805
2017
Q1 		$163K Buy
+11,400
New +$169K ﹤0.01% 799

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capstone Investment Advisors's LXRX Position: Q2 2017 in Review

Capstone Investment Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 11,400 shares — an estimated $163K sold.

Capstone Investment Advisors first reported a position in LXRX in Q1 2017 and held it in 1 quarter. The position peaked at $163K in Q1 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • Capstone Investment Advisors reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Capstone Investment Advisors sold 11,400 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $163K.
  • Capstone Investment Advisors first reported a position in Lexicon Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Capstone Investment Advisors's Lexicon Pharmaceuticals position peaked at $163K in Q1 2017.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Capstone Investment Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.